Alzheimer's disease (AD) involves dysfunction and degeneration of brain cells (neurons) which results in well-known symptoms like memory loss and difficulties to learn new tasks. An important player in the function and survival of neurons is an ion called calcium. In AD the levels of calcium in brain cells are abnormal and as a consequence these neurons do not function as they should and will even die over time. Thus, treatments which restore the normal levels and action of calcium in the diseased neurons of AD patients have a promising therapeutic potential. reMYND has discovered a novel candidate drug which restores the defective calcium levels in diseased neurons of AD brains to normal, healthy levels. In this way reMYND's drug would not only save these neurons from dysfunction and death, but it would also prevent healthy neurons to become diseased in first place.So far this drug has only been tested in animal models of AD. In these studies we have shown that the normal functions of calcium in rodent AD brain cells are restored and that consequently cognitive performance is improved. The aim of this proposal is to evaluate whether the candidate drug has the same actions in patients. First, studies need to be undertaken to demonstrate that the novel drug is safe in humans. In a second stage it will be evaluated whether the new drug can normalise the defective calcium-driven processes in AD patients, or even if first signs of efficacy on cognition can be observed. If successful a next step would entail larger studies to confirm more definitive the neuroprotective actions of the drug in AD patients.